Drugs / LAZUVAPAGON
LAZUVAPAGON
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02878096 | Jul → Aug 2016 | — | Sanwa Kagaku Kenkyusho Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03116191 | Feb → Dec 2017 | nocturnal enuresis | Sanwa Kagaku Kenkyusho Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAZUVAPAGON | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802162 ↗ |
| Known as | [14C]-SK-1404 | “each subject will receive a single PO dose of SK-1404 followed by an IV microtracer dose of \[14C\]-SK-1404.” NCT02878096 ↗ |
| Known as | KRP-N118 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802162 ↗ |
| Known as | SK-1404 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02878096 ↗ |
| Modality | Small molecule | — CHEMBL4802162 ↗ |
| Route | Oral | “single oral (PO) dose of carbon-14 (14C)-SK-1404” NCT02878096 ↗ |